New research reveals that individuals who come off blockbuster slimming jabs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who halt conventional lifestyle regimens.
Published data in a prominent medical journal shows that while overweight individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month once they quit.
"People buying these drugs must be aware of the risk of rapid weight regain when the therapy ends," stated researcher Dr. Susan Jebb.
Such speed of regain suggests a reversion to original weight within about a year and a half.
Comparing Approaches
The study, which looked at 37 of trials involving thousands of patients, compared the outcomes of the injectable medications with older methods.
Researchers emphasize that people who lose weight through lifestyle changes alone generally see a more gradual weight regain—approximately 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Doctors suggest the way of the injections is key to understanding the accelerated weight return.
GLP-1 drugs mimic a natural hormone called GLP-1, which controls hunger.
"Long-term administration of the hormone levels far above than the body's typical production might result in the body to produce less of its endogenous GLP-1, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication leads to appetite is uncontrolled, making overeating far more likely."
A Chronic Disease?
The NHS suggest the injections for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians contend that, given the high risk of relapse, the therapy might need to be long-term.
This opinion is reinforced by pharmaceutical companies, who state that the findings "highlight the chronic character of excess weight," akin to managing diseases like high blood pressure.
User Experiences
Users who have come off the medication explain a sudden return of appetite.
"It felt as if a switch flipping and you become starving," described one woman.
This difficulty is compounded if individuals have not adopted sustainable dietary or behavioural changes during therapy.
Widespread Use
Figures indicate that millions of people in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Adoption is greater among females compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
In conclusion, researchers stress that while the jabs are powerful agents for shedding pounds, they are not a permanent fix and long-term success hinges on ongoing behavioural changes.
